Keyphrases
Patients with Schizophrenia
46%
Chronic Phase
46%
Diagnostic Criteria
46%
Clinical Outcomes
46%
Anti-NMDAR Encephalitis
46%
Dissociative Disorders
46%
Rare Loss
46%
Nalmefene
46%
GRIN2D
46%
Social Outcomes
46%
Adult Autism Spectrum Disorder
46%
Exploratory pilot Study
46%
Adults with Autism Spectrum Disorder
46%
Dendritic Morphogenesis
46%
Chronic Social Defeat Stress
46%
Srs2
46%
N-methyl-D-aspartate Glutamate Receptor
46%
Glutamate Carboxypeptidase II (GCPII)
46%
Restless Genital Syndrome
46%
Psychiatric Symptoms
46%
Predictors of Remission
46%
JHU083
46%
Glutamine Antagonist
46%
Sleep Deficit
46%
EcoHIV
46%
Causal Impact
46%
Brain Cognition
46%
Remitters
46%
Rho Guanine nucleotide Exchange Factor
46%
Schizophrenia Spectrum Disorders
46%
Transient Epileptic Amnesia
46%
Induced Psychosis
46%
Activity-based Anorexia Model
46%
GRIN2C
35%
ARHGEF11
33%
Chronic Schizophrenia
33%
Social Awareness
31%
Social Impairment
31%
Center for Epidemiologic Studies Depression Scale (CES-D)
31%
Schizophrenia
29%
Glycogen Synthase kinase-3β (GSK-3β)
26%
Inflammatory Signature
23%
System Inflammation
23%
Manic Depression
23%
IgG Antibody
23%
NR2B
23%
People Living with HIV (PLHIV)
23%
Symptomatic Remission
23%
Social Avoidance
18%
Stress-susceptible
18%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammation
93%
Aripiprazole
93%
Anti N Methyl D Aspartate Receptor Encephalitis
93%
Olanzapine
93%
Risperidone
60%
Tolerability
55%
Symptom
53%
Akathisia
51%
Schizophrenia Spectrum Disorder
50%
Observational Study
46%
Clozapine
46%
Blonanserin
46%
Encephalitis
46%
Cohort Study
46%
Nalmefene
46%
Cross-Sectional Study
46%
Non Insulin Dependent Diabetes Mellitus
46%
Glutamate Carboxypeptidase II Inhibitor
46%
Elimination
46%
Comorbidity
46%
Agranulocytosis
46%
Lorlatinib
46%
Immunotherapy
31%
Antidepressant
31%
Lithium Carbonate
31%
Pathophysiology
23%
Glutamate Carboxypeptidase II
23%
Typical Antipsychotic
20%
Medical History
15%
Psychotropic Agent
15%
Preclinical Study
15%
Mixed Anxiety and Depression
15%
Clinical Study
15%
Mood Disorder
15%
Primary Culture
15%
Mouse Model
15%
Parkinson's Disease
15%
Virus Infection
15%
Anaplastic Lymphoma Kinase
14%
Brain Metastasis
14%
Non Small Cell Lung Cancer
14%
Adverse Drug Reaction
13%
Disease
12%
Antipsychotic
11%
Side Effect
10%
Norleucine
9%
Clinical Trial
7%
Drug Delivery System
7%
Receptor
6%
Epidemiology
6%
Medicine and Dentistry
Olanzapine
100%
Aripiprazole
93%
Anti N Methyl D Aspartate Receptor Encephalitis
93%
Schizophrenia Spectrum Disorder
65%
Risperidone
60%
Symptom
53%
Psychiatry
46%
Treatment of Depression
46%
Brain Function
46%
Nasal Cavity
46%
Maturation
46%
Loss of Function Mutation
46%
Glutamate Carboxypeptidase II Inhibitor
46%
Encephalitis
46%
Milnacipran
46%
Retrospective Cohort Study
46%
Centrosome
46%
Diagnosis of Mood Disorder
46%
Adult Attention Deficit Hyperactivity Disorder
46%
Agranulocytosis
46%
Lorlatinib
46%
Patient with Depression
31%
Immunotherapy
31%
Lithium Carbonate
31%
Antidepressant
31%
Cerebrospinal Fluid
31%
Glutamate Carboxypeptidase II
23%
Hazard Ratio
16%
Psychiatrist
15%
Outpatient
15%
Parkinson's Disease
15%
Immune System Function
15%
Logistic Regression Analysis
15%
Emergency Medical Technician
15%
Mood Disorder
15%
Primary Culture
15%
Environmental Factor
15%
Psychoactive Drug
15%
Clinical Global Impression
15%
Medical History
15%
Brief Psychiatric Rating Scale
15%
In Vitro
15%
Virus Infection
15%
Somatic Symptom Disorder
15%
Brain Metastasis
14%
Non Small Cell Lung Cancer
14%
Anaplastic Lymphoma Kinase
14%
Hopelessness
10%
Intron Retention
9%
GRIN2A
9%